• 前沿讲堂:Developing TCR-ba...
    2021-10-13
  • 2021年诺贝尔生理学或医学奖...
    2021-10-13
  • 前沿讲堂:神经损伤与修复
    2021-07-08

会员登录

用户名:
密码:

杨沛然

 

教育及工作

 

2008-2017              英国剑桥大学 (University of Cambridge) 学士、硕士、博士学位

2017-2020              美国哈佛大学医学院 (Harvard Medical School) 博士后

2021-                       中国医学科学院基础医学研究所&北京协和医学院基础学院引进人才

 

现任生理学系课题组长、博士研究生导师,加入院校准-长聘教职系列。

 

 

研究领域与方向

 

肺血管病和呼吸系统疾病研究

 

从分子、细胞和整体动物水平,结合多组学临床数据,研究肺动脉高压、尘肺病及慢阻肺等呼吸系统疾病发生发展中的病理生理学改变及重要分子机制;探索相关疾病的干预策略,寻找新靶点并进行临床前与转化实验。

 

课题组长期与国内相关领域顶尖研究团队、临床医院以及哈佛医学院、剑桥大学团队交流合作。

 

课题组招聘2021-2022

 

课题组计划招聘1-2助理研究员,需熟练掌握分子生物与生物化学实验技术,能够在课题组长指导下开展课题研究与基金申请工作,协助课题组长指导研究生。

 

课题组长期招收博士研究生/硕士研究生欢迎对本课题组研究方向感兴趣的同学报考。

 

 

联系方式:

peiranyang@ibms.pumc.edu.cn

北京市东城区东单三条5可胜大楼

 

代表性论文:

  1. 1.Yang P, Bocobo GA, Yu PB. Sotatercept for Pulmonary Arterial Hypertension. (Letter to Editor) N Engl J Med 2021 385(1):92-93. PMID: 34192439.
  2. 2.Yang P, Troncone L, Augur ZM, Kim SSJ, McNeil ME, Yu PB. The role of bone morphogenetic protein signaling in vascular calcification. (Review) Bone. 2020 141:115542. PMID: 32736145.
  3. 3.Yung LM#, Yang P#, Joshi S, Augur ZM, Kim SSJ, Bocobo GA, Dinter T, Troncone L, Chen PS, McNeil ME, Southwood M, Poli de Frias S, Knopf J, Rosas IO, Sako D, Pearsall RS, Quisel JD, Li G, Kumar R, Yu PB. ACTRIIA-Fc rebalances activin/GDF versus BMP signaling in pulmonary hypertension. Sci Transl Med. 2020 12(543):eaaz5660. PMID: 32404506.
  4. 4.Yang P#, Read C#, Kuc RE, Nyimanu D, Williams TL, Crosby A, Buonincontri G, Southwood M, Sawiak SJ, Morrell NW, Davenport AP, Maguire JJ. A novel cyclic biased agonist of the apelin receptor, MM07, is disease modifying in the rat monocrotaline model of pulmonary arterial hypertension. Br J Pharmacol. 2019 176(9):1206-1221. PMID: 30710493.
  5. 5.Yang P, Read C, Kuc RE, Buonincontri G, Southwood M, Torella R, Upton PD, Crosby A, Sawiak SJ, Carpenter TA, Glen RC, Morrell NW, Maguire JJ*, Davenport AP*. Elabela/Toddler Is an endogenous agonist of the apelin APJ receptor in the adult cardiovascular system, and exogenous administration of the peptide compensates for the downregulation of its expression in pulmonary arterial hypertension. Circulation. 2017 135(12):1160-1173. PMID:28137936.
  6. 6.Yang P, Kuc RE, Brame AL, Dyson A , Singer M, Glen RC, Cheriyan J, Wilkinson IB, Davenport AP, Maguire JJ. [Pyr1]Apelin(1-12) is a biologically active ACE2 metabolite of the endogenous cardiovascular peptide [Pyr1]Apelin-13. Front Neurosci. 2017 11:92. PMID:28293165.
  7. 7.Read C#, Fitzpatrick CM#, Yang P#, Kuc RE, Maguire JJ*, Glen RC*, Foster RE*, Davenport AP*. Cardiac action of the first G protein biased small molecule apelin agonist. Biochem Pharmacol. 2016 116:63-72. PMID:27475715.
  8. 8.Yang P, Maguire JJ, Davenport AP. Apelin, Elabela/Toddler, and biased agonists as novel therapeutic agents in the cardiovascular system. (Review) Trends Pharmacol Sci. 2015 36(9):560-567. PMID: 26143239.